Cargando…

HRAS Q61L Mutation as a Possible Target for Non-Small Cell Lung Cancer: Case Series and Review of Literature

Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathiot, Laurent, Herbreteau, Guillaume, Robin, Siméon, Fenat, Charlotte, Bennouna, Jaafar, Blanquart, Christophe, Denis, Marc, Pons-Tostivint, Elvire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139372/ https://www.ncbi.nlm.nih.gov/pubmed/35621690 http://dx.doi.org/10.3390/curroncol29050300

Ejemplares similares

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

Molecular minimal residual disease in resected non-small cell lung cancer (NSCLC): results of specifically designed interventional clinical trials eagerly awaited
por: Denis, Marc G., et al.
Publicado: (2023)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

A fatal case associated with Catabacter hongkongensis bacteremia in lung cancer patient: A case report
por: Mandin, Valentin, et al.
Publicado: (2022)

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas
por: Geyer, Felipe C., et al.
Publicado: (2018)

Gemcitabine-capecitabine: a therapeutic option in previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma
por: Pons-Tostivint, Elvire
Publicado: (2023)

Transcriptome of melanoma cells from two mouse models, Tyr:NRas(Q61K)and Tyr:Rack1-HA, Tyr:NRas(Q61K)
por: Campagne, Cécil, et al.
Publicado: (2017)

HRAS mutation prevalence and associated expression patterns in pheochromocytoma
por: Stenman, Adam, et al.
Publicado: (2016)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Mechanism of the Exchange Reaction in HRAS from Multiscale Modeling
por: Kapoor, Abhijeet, et al.
Publicado: (2014)

Phacomatosis pigmentokeratotica and precocious puberty associated with HRAS mutation
por: Martin, R.J., et al.
Publicado: (2017)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

MTH1 expression is required for effective transformation by oncogenic HRAS
por: Giribaldi, Maria G., et al.
Publicado: (2015)

The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma
por: Wan, Xiaohua, et al.
Publicado: (2017)

Analysis of FGFR3 and HRAS genes in patients with bladder cancer
por: Homami, Ameneh, et al.
Publicado: (2020)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma
por: Miller, Michael B., et al.
Publicado: (2016)

WDR76 mediates obesity and hepatic steatosis via HRas destabilization
por: Park, Jong-Chan, et al.
Publicado: (2019)

Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck
por: Sasaki, Eiichi, et al.
Publicado: (2020)

Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation
por: Zhao, Jidong, et al.
Publicado: (2021)

HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
por: Bièche, Ivan, et al.
Publicado: (2021)

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
por: Liverani, Chiara, et al.
Publicado: (2023)

Epitranscriptic regulation of HRAS by N(6)-methyladenosine drives tumor progression
por: Pan, Yongbo, et al.
Publicado: (2023)

Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma
por: Denis, Iza, et al.
Publicado: (2014)

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer
por: Cathcart-Rake, Elizabeth, et al.
Publicado: (2014)

Metabolomic and transcriptomic profiling of hepatocellular carcinomas in Hras12V transgenic mice
por: Fan, Tingting, et al.
Publicado: (2017)

Functional robustness of adult spermatogonial stem cells after induction of hyperactive Hras
por: Yamada, Makiko, et al.
Publicado: (2019)

Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS
por: Eijkelenboom, Astrid, et al.
Publicado: (2019)

Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS
por: Chen, Yi-Ting, et al.
Publicado: (2020)

All over the place: deciphering HRAS signaling from different subcellular compartments
por: Kolch, Walter, et al.
Publicado: (2019)

Correction: Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
por: Odeniyide, Patience, et al.
Publicado: (2022)

HRas and Myc synergistically induce cell cycle progression and apoptosis of murine cardiomyocytes
por: Boikova, Aleksandra, et al.
Publicado: (2022)

WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS
por: Hu, Yunlong, et al.
Publicado: (2023)

Dyrk2 gene transfer suppresses hepatocarcinogenesis by promoting the degradation of Myc and Hras
por: Kamioka, Hiroshi, et al.
Publicado: (2023)

Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors
por: Nigam, Aradhya, et al.
Publicado: (2023)

Murine models of HRAS-mediated cutaneous skeletal hypophosphatemia syndrome suggest bone as the FGF23 excess source
por: Ovejero, Diana, et al.
Publicado: (2023)

Treatment time interval in breast cancer: A population‐based study on the impact of type and number of cancer centres attended
por: Martinez, Amalia, et al.
Publicado: (2022)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rmmotql3tktcj5kerpb2k3e0bd